Race Oncology Ltd is advancing the development of a reformulated chemotherapy drug aimed at reducing severe side effects, particularly cardiac-related risks, while preserving or improving efficacy. In this episode of After Market with Jonathan Jackson, CEO and managing director Daniel Tillett highlighted the drug’s potential to work alongside anthracyclines, a common class of chemotherapy agents, to enhance patient safety and treatment outcomes. The company is preparing for clinical trials to evaluate the drug’s performance in human subjects.